Vanguard Global Advisers’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$880K Sell
87,727
-4,021
-4% -$37.2K ﹤0.01% 1798
2026
Q2
$768K Sell
91,748
-4,582
-5% -$41.8K ﹤0.01% 1894
2026
Q1
$868K Buy
+96,330
New +$1.52M ﹤0.01% 1733

Other funds holding ADMA

Vanguard Global Advisers's ADMA Position: Q3 2026 in Review

Vanguard Global Advisers reduced its ADMA Biologics (ADMA) stake by 4.4% in Q3 2026, selling an estimated $37.2K and leaving 87,727 shares worth $880K. The position accounts for ﹤0.01% of the portfolio, ranked #1798.

Vanguard Global Advisers first reported a position in ADMA in Q1 2026 and has held it in 3 quarters since. 330 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

  • Vanguard Global Advisers held 87,727 shares of ADMA Biologics worth $880K as of Q3 2026.
  • Vanguard Global Advisers sold 4,021 ADMA Biologics shares in Q3 2026, an estimated $37.2K.
  • ADMA Biologics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1798 holding.
  • Vanguard Global Advisers first reported a position in ADMA Biologics in Q1 2026 and has held it in 3 quarters since.
  • 330 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.